Phase 2 study to assess safety and efficacy of OBE022 to delay birth after oral administration in pregnant women
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs OBE 022 (Primary)
- Indications Preterm labour
- Focus Therapeutic Use
- Acronyms PROLONG
- 15 Aug 2017 According to an ObsEva media release, commencement of this trial is expected in the fourth quarter of 2017, with top-line data release expected around year end 2018.
- 18 May 2017 ObsEva expects to initiate this trial in 2H 2017, according to a company media release.
- 17 Jan 2017 New trial record